








OPEN ACCESS

Original research

Impact of cardiometabolic multimorbidity and ethnicity on cardiovascular/renal complications in patients with COVID-19

Tom Norris ¹, Cameron Razieh,² Francesco Zaccardi,^{1,2} Thomas Yates,² Nazrul Islam,³ Clare L Gillies,² Yogini V Chudasama,² Alex V Rowlands,² Melanie J Davies,² Gerry P McCann ⁴, Amitava Banerjee ⁵, Carolyn S P Lam,⁶ Annemarie B Docherty,⁷ Peter JM Openshaw,⁸ J Kenneth Baillie,⁹ Malcolm Gracie Semple ¹⁰, Claire Alexandra Lawson ^{1,4}, Kamlesh Khuntj,^{1,2} ISARIC4C investigators

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/heartjnl-2021-320047>).

For numbered affiliations see end of article.

Correspondence to

Dr Tom Norris, Leicester Real World Evidence Unit, Leicester General Hospital, Leicester, UK; tdn9@leicester.ac.uk

CAL and KK are joint senior authors.

Received 21 July 2021
Accepted 8 November 2021

ABSTRACT

Objective Using a large national database of people hospitalised with COVID-19, we investigated the contribution of cardio-metabolic conditions, multimorbidity and ethnicity on the risk of in-hospital cardiovascular complications and death.

Methods A multicentre, prospective cohort study in 302 UK healthcare facilities of adults hospitalised with COVID-19 between 6 February 2020 and 16 March 2021. Logistic models were used to explore associations between baseline patient ethnicity, cardiometabolic conditions and multimorbidity (0, 1, 2, >2 conditions), and in-hospital cardiovascular complications (heart failure, arrhythmia, cardiac ischaemia, cardiac arrest, coagulation complications, stroke), renal injury and death.

Results Of 65 624 patients hospitalised with COVID-19, 44 598 (68.0%) reported at least one cardiometabolic condition on admission. Cardiovascular/renal complications or death occurred in 24 609 (38.0%) patients. Baseline cardiometabolic conditions were independently associated with increased odds of in-hospital complications and this risk increased in the presence of cardiometabolic multimorbidity. For example, compared with having no cardiometabolic conditions, 1, 2 or ≥ 3 conditions was associated with 1.46 (95% CI 1.39 to 1.54), 2.04 (95% CI 1.93 to 2.15) and 3.10 (95% CI 2.92 to 3.29) times higher odds of any cardiovascular/renal complication, respectively. A similar pattern was observed for all-cause death. Compared with the white group, the South Asian (OR 1.19, 95% CI 1.10 to 1.29) and black (OR 1.53 to 95% CI 1.37 to 1.72) ethnic groups had higher risk of any cardiovascular/renal complication.

Conclusions In hospitalised patients with COVID-19, cardiovascular complications or death impacts just under half of all patients, with the highest risk in those of South Asian or Black ethnicity and in patients with cardiometabolic multimorbidity.

BACKGROUND

As of April 2021, SARS-CoV-2 has infected over 140 million people and claimed over 3 million lives

worldwide. After infection, the course of the disease (COVID-19) varies, ranging from asymptomatic mild infection to severe complications and death. People who require hospital admission have the worse outcomes, with a mortality risk of 10%–26% in USA and the UK.^{1,2}

Individuals from non-Caucasian ethnic groups or with multiple chronic conditions have been found to be susceptible to severe COVID-19 disease, in-hospital cardiovascular complications and death.³ In particular, impaired cardiometabolic health has emerged as an important accelerator of severe COVID-19 disease. Over 25% of patients hospitalised with COVID-19 have cardiometabolic conditions, including hypertension, obesity, diabetes and chronic cardiac disease.⁴ These morbidities have been described as the primary chronic conditions that lead to worsening COVID-19 outcomes.^{5,6} In addition to the baseline risk associated with cardiometabolic conditions, recent studies have shown that COVID-19 can cause acute cardiovascular injury including arrhythmias, cardiac arrest, myocardial infarction and heart failure.^{7,8} These insults can in turn lead to chronic cardiovascular damage or death, even in those without existing cardiovascular disease.^{9,10} Possible mechanisms linking COVID-19 with cardiovascular complications include the release of cytokines ('cytokine storm'), dysregulation of the renin-angiotensin-aldosterone system and coagulation systems, and plaque rupture during the acute infection phase.¹¹

Because people with COVID-19 often have a combination of different high-risk characteristics, it can be difficult to know which are the most important or whether some or all of the higher risk of COVID-19 complications in people who are non-Caucasian is explained by their cardiometabolic conditions. In order to unpick the relative importance of the various factors contributing to adverse COVID-19 prognosis, large, well-phenotyped samples are required, with good coverage of these contributing factors. Accordingly, this study investigated the contribution of multiple cardiometabolic conditions and patient ethnicity, to the risk of cardiovascular/renal complications and death, in



© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.

To cite: Norris T, Razieh C, Zaccardi F, et al. *Heart* Epub ahead of print: [please include Day Month Year]. doi:10.1136/heartjnl-2021-320047

Table 1 Patient characteristics, stratified by presence of cardiovascular complications (n=65 624)

	Patients not experiencing cardiovascular complication (n=48 996)	Patients experiencing cardiovascular complication (n=16 628)	Standardised differences*
<i>Sex</i>			
Male	25 219 (51.5)	9 672 (58.2)	0.13
Female	23 777 (48.5)	6 956 (41.8)	
Age on admission (years)	71 (55, 83)	78 (66, 86)	0.40
<i>Ethnicity</i>			
White	41 234 (84.2)	14 354 (86.3)	0.07
South Asian	3 056 (6.2)	868 (5.2)	
Black	1 248 (2.6)	461 (2.8)	
Other	3 458 (7.1)	945 (5.7)	
<i>In-hospital cardiovascular complications</i>			
Arrhythmia	–	4 446 (27.4)	
Cardiac ischaemia	–	857 (5.3)	
Cardiac arrest	–	1 370 (8.4)	
Coagulation complications	–	2 088 (12.9)	
Stroke	–	1 043 (6.4)	
Heart failure	–	2 297 (14.1)	
Renal injury	–	9 968 (60.5)	
<i>Baseline cardiometabolic comorbidities</i>			
Diabetes	8 276 (16.9)	4 152 (25.0)	0.20
Chronic cardiac disease	12 872 (26.3)	7 265 (43.7)	0.37
Hypertension	20 552 (42.0)	9 425 (56.7)	0.30
Chronic kidney disease	6 126 (12.5)	4 362 (26.2)	0.35
Obesity	6 030 (12.3)	2 702 (16.3)	0.11

Data are reported as n(%) for categorical variables and median (IQR) for continuous variables.

*Standardised difference = difference in means or proportions divided by SE; imbalance defined as absolute value >0.10.

a large nationally representative sample of people hospitalised with COVID-19.

METHODS

Population

We used data from the International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC) WHO Clinical Characterisation Protocol UK (CCP-UK) for severe emerging infection. Developed by ISARIC and WHO in 2009, the protocol was reactivated on 17 January 2020 in response to the SARS-CoV-2 pandemic. The protocol and all study materials for this actively recruiting prospective cohort can be accessed online (<https://isaric4c.net>). The ISARIC WHO CCP-UK study was registered at <https://www.isrctn.com/ISRCTN66726260> and designated an Urgent Public Health Research Study by the National Institute for Health Research.

Sample

Patients aged ≥ 18 years who were admitted to hospital between 6 February 2020 and 16 March 2021 with a confirmed COVID-19 diagnosis were included. Confirmation of SARS-CoV-2 was done using reverse transcriptase PCR. Highly suspected cases were eligible for inclusion, given that SARS-CoV-2 was an emergent pathogen at the time of protocol activation and laboratory confirmation was dependent on local availability of testing. The enrolment criterion 'high likelihood of infection' reflects that a preparedness protocol cannot assume that a diagnostic test will be available for an emergent pathogen. Site training emphasises that only patients who tested positive for COVID-19 were eligible for enrolment. All patients who provided biological samples were required to provide informed, written consent. If patients only provided routinely collected clinical data, written

consent was not required (further details can be found in online supplemental text S1).

Patients who had missing outcome or sex data or were recipients of an organ transplant, immunosuppression therapies or had rare diseases likely to significantly increase the risk of infections (such as severe combined immunodeficiency) were excluded. As of 16 March 2021, 140 975 patients were included in the CCP-UK Study of which 138 455 (98.2%) had a confirmed diagnosis of COVID-19. Of these, 65 624 (46.6%) had the relevant outcome and covariate data for analysis. Online supplemental figure S1 shows how the final sample was derived. Differences in a number of covariates between those included and excluded are provided in online supplemental table S1) and are summarised using standardised differences which are less dependent on the sample size of each group.¹²

Exposures

Cardiometabolic comorbidities

Data on baseline cardiometabolic comorbidities including hypertension, obesity, diabetes, chronic cardiac conditions and chronic kidney disease were extracted from clinical records. Further information regarding how these variables were classified can be found in online supplemental text S1. We created a dichotomous variable representing the presence of any of the baseline cardiometabolic comorbidities. In addition, to assess the effect of cardiometabolic multimorbidity on outcomes, we created a count variable, summing the number of cardiometabolic morbidities and categorising them as 1, 2 and ≥ 3 .

Ethnicity

Ethnicity was coded into four groups, reflecting the most prevalent ethnic groups in the 2011 census in England and Wales,¹³

Table 2 Association between baseline cardiometabolic comorbidities, cardiovascular/renal complications and all-cause death

	Primary outcomes			Secondary outcomes					
	Any complication OR (95% CI)	All-cause death	Heart failure OR (95% CI)	Arrhythmia OR (95% CI)	Cardiac ischaemia OR (95% CI)	Cardiac arrest OR (95% CI)	Coagulation complications OR (95% CI)	Stroke OR (95% CI)	Renal injury OR (95% CI)
Any cardiometabolic comorbidity (ref. No)	1.93 (1.84 to 2.02)	1.21 (1.16 to 1.27)	4.19 (3.56 to 4.94)	1.69 (1.56 to 1.83)	2.61 (2.11 to 3.23)	1.24 (1.09 to 1.42)	1.49 (1.34 to 1.66)	1.19 (1.02 to 1.38)	2.08 (1.96 to 2.20)
Number of cardiometabolic comorbidities (ref. 0)*									
1	1.46 (1.39 to 1.54)	1.11 (1.05 to 1.17)	2.23 (1.86 to 2.67)	1.44 (1.31 to 1.57)	1.88 (1.48 to 2.39)	1.04 (0.89 to 1.22)	1.37 (1.21 to 1.54)	1.19 (1.00 to 1.41)	1.52 (1.42 to 1.62)
2	2.04 (1.93 to 2.15)	1.22 (1.16 to 1.29)	4.59 (3.85 to 5.46)	1.74 (1.58 to 1.91)	2.60 (2.05 to 3.30)	1.40 (1.19 to 1.63)	1.38 (1.21 to 1.58)	1.17 (0.98 to 1.41)	2.18 (2.04 to 2.33)
>2	3.10 (2.92 to 3.29)	1.42 (1.34 to 1.51)	8.01 (6.73 to 9.53)	2.23 (2.02 to 2.47)	4.24 (3.35 to 5.38)	1.46 (1.23 to 1.73)	2.03 (1.77 to 2.32)	1.21 (0.99 to 1.48)	3.41 (3.18 to 3.66)

*Separate models, adjusted for sex, age and ethnicity.

as follows: white, South Asian, black and other (East and West Asian, Arab, Latin American, Aboriginal/First Nations, other).

Covariates

Sex was coded as female/male. Age was measured to the nearest year using the difference between date of birth and the admission date.

Outcomes

The primary outcomes were (1) A dichotomous variable representing any in-hospital cardiovascular or renal complication; and (2) All-cause death. In-hospital cardiovascular complications were defined clinically in patient healthcare records and extracted by local investigators and included stroke, heart failure, arrhythmia, ischaemia, cardiac arrest and coagulation disorders (abnormal coagulation identified by abnormal prothrombin time or activated partial thromboplastin time). Due to the intrinsic nature of cardiovascular and renal dysfunction we also included 'acute renal injury' in the list of complications. These individual cardiovascular/renal complications were considered secondary outcomes. Further information regarding how these variables were defined can be found in online supplemental text S1.

Statistical analysis

Descriptive statistics are presented as number (%) and median (25th and 75th centiles) for categorical and continuous data, respectively, with differences between those with and without cardiovascular complications in these characteristics examined using standardised differences. To investigate the relationship between cardiometabolic comorbidities, ethnicity and outcomes, we constructed three models.

Model 1: Unadjusted associations between the exposures: (1) 'any' cardiometabolic comorbidity, (2) Cardiometabolic multimorbidity count and (3) Ethnic group, and the primary outcomes: (1) 'any' in-hospital cardiovascular/renal complication; (2) In-hospital death and the secondary outcomes: each individual cardiovascular/renal complication.

Model 2: Model 1 exposures (1–2), adjusted for age, sex and ethnicity and Model 1 exposures (3), adjusted for age, sex and baseline cardiometabolic comorbidities. Age was entered into the model as a restricted cubic spline, with four knots placed at the 20th, 40th, 60th and 80th centiles of the age distribution, with the reference value set to the mean age of the sample (70 years of age). This was repeated for the secondary outcomes.

Model 3: To investigate whether the relationship between baseline cardiometabolic comorbidities and 'any' in-hospital complications differed according to ethnicity status, we entered first-order interaction terms into Model 2, between ethnic group and 'any' cardiometabolic comorbidity and between ethnic group and the multimorbidity count variable. Interactions were formally assessed using the Wald test, with $p < 0.05$ indicating a significant interaction term. Predicted probabilities for each interaction term and outcome were estimated and plotted using Stata's `postestimation` 'margins' and 'marginsplot' commands.

Supplementary analyses

We repeated Models 1 and 2 replacing the dichotomous 'any' cardio-metabolic comorbidity exposure variable with each individual baseline cardio-metabolic comorbidity. Furthermore, we repeated Models 1 to 3 using a composite outcome representing 'any complication or all-cause death' to account for the competing risk of death in assessing in-hospital complications.




Figure 1 Associations between baseline cardiometabolic multimorbidity and (1) Any in-hospital cardiovascular/renal complication and (2) All-cause death (adjusted for sex, age and ethnicity).

A final set of models was constructed to investigate the separate and combined associations between baseline cardiometabolic comorbidities, in-hospital cardiovascular/renal complications and death. For this model, we created a single variable which categorised patients into four groups: patients with no baseline cardiometabolic morbidities or in-hospital cardiovascular/renal complications (reference group); patients with baseline cardiometabolic morbidities only; patients with in-hospital cardiovascular/renal complications only, and patients with both baseline cardiometabolic morbidities and in-hospital cardiovascular/renal complications. Logistic regression was then used to estimate the association between this categorical variable and death, with adjustment for sex, age and ethnicity.

All analyses were conducted in Stata V.16 (Stata Corp, College Station, Texas, USA). Data are reported with 95% CI unless reported otherwise.

Patient and public involvement

This was an urgent public health research study in response to a public health emergency of international concern. Patients or the public were not involved in the design, conduct or reporting of this rapid response research.

RESULTS

The sample comprised 34 891 men (53.2%), had a median age of 73 years (IQR: 58–84) and 55 588 (84.7%) of individuals were of ‘White’ ethnicity (table 1). Over two-thirds of individuals (44 598; 68.0%) reported at least one cardiometabolic condition on admission, with 30.5%, 22.8% and 14.7% of the sample reporting one, two or more than two baseline cardiometabolic conditions, respectively; 3612 (5.5%) individuals required an invasive ventilation procedure (tracheal intubation or tracheostomy) while in hospital. More than a quarter

of the sample experienced a cardiovascular/renal complication while in hospital (n=16 628, 25.3%), of which 9702 (58.3%) patients survived and 6926 (n=41.7%) died. Of patients who experienced a cardiovascular/renal complication 2133 (12.8%) required an invasive ventilation procedure while in hospital, compared with 1479 (3.0%) of those who did not. Of the patients, 8293 (16.9%) died who did not experience a cardiovascular/renal complication or in-hospital death, resulting in a total of 15 219 (23.2%) patient deaths. Of the patients, 1685 (46.7%) who had required an invasive ventilation procedure while in hospital died, compared with 13 478 (21.8%) of those who did not require such intervention.

In total, 24 921 (38.0%) of the sample experienced either a cardiovascular/renal complication or died.

Primary outcomes: any cardiovascular/renal complications and all-cause death

Baseline cardiometabolic comorbidity

Unadjusted associations between baseline cardiometabolic comorbidity, multimorbidity, cardiovascular/renal complications and all-cause death are shown in online supplemental table S2. Having any baseline cardiometabolic comorbidity was associated with more than twice the odds of experiencing a cardiovascular/renal complication (OR 2.54, 95% CI 2.43 to 2.65). The association between baseline cardio-metabolic comorbidities and increased risk of in-hospital cardiovascular/renal complications remained following adjustment for age, sex and ethnicity (table 2, figure 1). For example having any baseline cardiometabolic comorbidity was associated with 1.93 (95% CI 1.84 to 2.02) times higher odds of experiencing a cardiovascular/renal complication. In terms of multimorbidity, individuals with one, two or more than two baseline comorbidities had 1.46 (95% CI 1.39 to 1.54), 2.04 (95% CI 1.93 to 2.15) and 3.10 (95% CI

Table 3 Association between ethnicity, cardiovascular/renal complications and all-cause death

	Primary outcome			Secondary outcome					
	Any complication OR (95% CI)	All-cause death	Heart failure OR (95% CI)	Arrhythmia OR (95% CI)	Cardiac ischaemia OR (95% CI)	Cardiac arrest OR (95% CI)	Coagulation complications OR (95% CI)	Stroke OR (95% CI)	Renal injury OR (95% CI)
<i>Ethnicity (ref: white)</i>									
South Asian	1.13 (1.04 to 1.22)	1.27 (1.16 to 1.40)	0.97 (0.78 to 1.22)	0.82 (0.70 to 0.95)	1.49 (1.13 to 1.98)	1.83 (1.49 to 2.23)	0.97 (0.81 to 1.17)	1.10 (0.82 to 1.47)	1.19 (1.07 to 1.31)
Black	1.46 (1.30 to 1.63)	1.18 (1.03 to 1.36)	1.02 (0.75 to 1.41)	0.83 (0.67 to 1.04)	0.78 (0.45 to 1.36)	2.12 (1.62 to 2.79)	1.32 (1.04 to 1.68)	0.96 (0.61 to 1.51)	1.77 (1.56 to 2.02)
Other	1.05 (0.97 to 1.14)	1.07 (0.98 to 1.16)	1.00 (0.82 to 1.23)	0.86 (0.74 to 0.99)	1.40 (1.07 to 1.83)	1.17 (0.94 to 1.47)	0.96 (0.81 to 1.15)	1.15 (0.88 to 1.49)	1.10 (1.00 to 1.21)

Adjusted for sex, age and baseline cardiometabolic comorbidities.

2.92 to 3.29) times higher odds, respectively, of experiencing a cardiovascular/renal complication.

Adjusted associations between baseline cardiometabolic comorbidities, multimorbidity and all-cause death are shown in [table 2](#). The presence of any baseline cardiometabolic comorbidity was associated with 1.21 (95% CI 1.16 to 1.27) times higher odds of death. Progressively higher odds of death were observed with an increasing number of baseline cardiometabolic comorbidities, such that individuals with one, two or more than two comorbidities demonstrated odds which were 1.11 (95% CI 1.05 to 1.17), 1.22 (95% CI 1.16 to 1.29) and 1.42 (95% CI 1.34 to 1.51) times higher than individuals without baseline comorbidities.

Ethnicity

Unadjusted associations between ethnic group and cardiovascular/renal complications are shown in online supplemental table S2. Following adjustment for age, sex and baseline cardiometabolic comorbidities, patients of South Asian (OR 1.13, 95% CI 1.04 to 1.22) or black (1.46, 95% CI 1.30 to 1.63) ethnicity demonstrated increased odds of experiencing a cardiovascular/renal complication, compared with the white ethnic group ([table 3](#)). However, we did not find any strong evidence in support of an interaction between ethnicity and cardiometabolic comorbidities (online supplemental tables S3 and S4), (online supplemental figures S2 and S3).

After adjusting for sex, age and baseline cardiometabolic comorbidities, the South Asian (OR 1.27; 95% CI 1.16 to 1.40) and black ethnic groups (OR 1.18; 95% CI 1.03 to 1.36) were at significantly higher risk of all-cause death compared with the white group ([table 3](#)). The magnitude of these associations remained largely unchanged following adjustment for baseline cardiometabolic comorbidities.

Secondary outcomes: individual cardiovascular/renal complications

Baseline cardio-metabolic comorbidity

The association between baseline comorbidities and individual complications can be seen in [table 2](#) and [figure 2A,B](#). A pattern of increasing odds of complications with an increasing number of baseline cardio-metabolic conditions was observed for heart failure, arrhythmia, cardiac ischaemia and acute renal injury.

Ethnicity

The South Asian group was almost twice as likely to experience cardiac arrest (OR 1.83, 95% CI 1.49 to 2.23) and almost 50% more likely to experience cardiac ischaemia (OR 1.49, 95% CI 1.13 to 1.98) than the white group. The black group was more than twice as likely to experience cardiac arrest (OR 2.12, 95% CI 1.62 to 2.79) and over 75% more likely to experience acute renal injury (OR 1.77, 95% CI 1.56 to 2.02), compared with the white group ([table 3](#)).

Supplementary analyses

In adjusted models, chronic kidney disease exhibited the strongest association with the likelihood of experiencing any cardiovascular/renal complication (OR 2.02, 95% CI 1.93 to 2.11), while obesity conferred the greatest odds of death (OR 1.34, 95% CI 1.26 to 1.43) (online supplemental table S5).

We observed a consistent pattern of associations between cardiometabolic comorbidity, ethnicity and the composite outcome representing 'cardiovascular/renal complication or all-cause death' (online supplemental tables S6 and S7 and online supplemental figures S4 and S5).




Figure 2 (A) Associations between baseline cardiometabolic multimorbidity and each in-hospital cardiovascular/renal complication (adjusted for sex, age and ethnicity). (B) Associations between baseline cardiometabolic multimorbidity and each in-hospital cardiovascular/renal complication (adjusted for sex, age and ethnicity).

Compared with patients with no baseline cardiometabolic conditions or in-hospital complications, patients with baseline cardiometabolic comorbidities only had 20% higher odds of death (OR 1.20, 95% CI 1.13 to 1.27). Those with a baseline cardiometabolic condition and experiencing an in-hospital complication had over three times higher odds of death, compared with those with neither (OR: 3.17, 95% CI 2.98 to 3.37). However, those who had no baseline cardiometabolic conditions, but who subsequently experienced an

in-hospital cardiovascular/renal complication, had almost four times higher odds of death, relative to patients with neither (OR 3.92, 95% CI 3.57 to 4.29).

DISCUSSION

In 65 624 hospitalised patients with COVID-19, 68% had at least one cardiometabolic comorbidity on admission and 38% experienced an in-hospital cardiovascular/renal complication or

died. The presence of cardiometabolic conditions and multimorbidity on admission increased the risk of experiencing in-hospital cardiovascular/renal complications and death. Risk of in-hospital complications were also increased in people from South Asian and black ethnicity groups, independent of their cardiometabolic status on admission to hospital.

Several studies have previously reported that the presence of chronic conditions is associated with a more severe course and progression of COVID-19, ultimately culminating in an increased risk of mortality.^{14–16} There has been less attention on the short-term morbidity events which are likely associated with significant long-term morbidity. The most common complication observed was acute renal injury, which is associated with increased long-term risk of mortality, requirement for dialysis and an increase in cardiovascular events.^{17–19} While cardiac ischaemia was the least common cardiovascular/renal complication observed (5.3%), if left untreated, the ischaemia can progress to ischaemic heart disease which is the leading cause of death globally.²⁰

Our study extends the findings from previous studies,^{14–16 21 22} which were largely based on either significantly smaller samples or in single healthcare settings or cities, and which demonstrated an increased risk of severe COVID-19 illness in those with pre-existing conditions. While associations between individual comorbidities and in-hospital complications differed in their magnitude, a consistent finding was the increasing risk of all complications, aligned with the increasing number of cardiometabolic morbidities at baseline. This multimorbidity association was strongest for the risk of heart failure, with those reporting more than two cardio-metabolic conditions having more than eight times higher odds, compared with patients with no cardio-metabolic conditions. Previous studies have suggested that acute heart failure can be the primary presenting manifestation of COVID-19 infection.²³ An early study in China observed that 40% of fatalities in hospitalised critically ill patients with COVID-19 were associated with myocardial damage and heart failure.²⁴ Whether this heart failure represents a new cardiomyopathy or an exacerbation of previously undiagnosed heart failure is however, unknown.²⁵

While we did not observe strong evidence of a modifying effect of ethnicity on the relationship between cardiometabolic comorbidities and in-hospital complications (only), we did find some evidence that the association between cardiometabolic comorbidities and the composite outcome of cardiovascular/renal complications or death, was modified by ethnicity (online supplemental figures S4 and S5). This could be due to a modifying effect of ethnicity on the relationship between cardiometabolic comorbidities and death, which we did observe weak evidence for ($p_{\text{(interaction)}}=0.03$, models not shown). Belonging to an ethnic minority group is associated with elevated risk for severe illness from COVID-19,^{26 27} likely resulting from a combination of socioeconomic, cultural/lifestyle factors, genetic predisposition, or pathophysiological differences in susceptibility or response to infection.²⁷ Such susceptibilities include a higher prevalence of cardiometabolic conditions including insulin resistance, obesity and hypertension,²⁸ though adjustment for baseline comorbidities (eg, diabetes status) did not attenuate the increased risk in these groups.

Strengths and limitations

These data were collected prospectively across 302 hospitals and represent a large proportion (approximately 40%) of people hospitalised with COVID-19 in the UK, thus increasing the

generalisability of our findings. Unlike our study, other smaller, or single-centre studies have typically focused either exclusively on patients who received critical care, or on one type of complication and lack systematic approaches to data collection.²⁹ In terms of limitations, the complications and comorbidities that were captured were predefined by a pragmatic outbreak preparedness study protocol which was developed prior to the emergence of COVID-19 and which may lack the granular details which could be instead collected in ad hoc cohort studies or trials (ie, brain natriuretic peptide or echocardiography). All medical conditions, which were clinically defined following the diagnostic procedures deemed relevant by the healthcare professional, were extracted from clinical records and inputted from the local health professionals in charge of each individual's care. Furthermore, the combined definition of 'chronic cardiac disease' combines a variety of conditions (eg, coronary artery disease, heart failure, congenital heart disease, cardiomyopathy and rheumatic heart disease) which may potentially confer distinct and diverging pathophysiological responses to COVID-19. In addition, we did not have data regarding the severity or duration of the cardiometabolic comorbidities experienced, which would have provided a more precise estimation of the burden of cardiometabolic disease at baseline. Relatedly, a lack of sociodemographic and lifestyle factors (eg, smoking habits and physical activity) included in the study protocol means that the possibility of residual confounding biasing our estimates cannot be excluded.

Our study highlights the importance of adequate risk factor control (ie, regular monitoring) in reducing the risk of hospital admission and complications if infected with COVID-19. This is especially important in individuals already at an increased risk of developing cardiometabolic conditions such as those with prediabetes, prehypertension or those who are overweight. Hospitalised patients with COVID-19 who survive after cardiovascular/renal complications are likely to experience long-term morbidity. As such, governments, policy makers, healthcare planners and front-line healthcare workers should anticipate an increased

Key messages

What is already known about this subject?

- Findings from several small and regional studies suggest that certain patient groups admitted to hospital with COVID-19 are more susceptible to in-hospital cardiovascular complications and death.

What does this study add?

- In this cohort of 65 624 patients with COVID-19, in-hospital cardiovascular/renal complications or death occurred in 38%. A greater number of cardiometabolic comorbidities on admission and being of black or South Asian ethnicity increased odds of cardiovascular/renal complications. A similar pattern was observed for all-cause death.

How might this impact on clinical practice?

- Our findings indicate the prognostic relevance of several risk factors on the risk of in-hospital complications if infected with COVID-19. This is especially important in individuals already at an increased risk of developing cardiometabolic conditions such as those with prediabetes, prehypertension or those who are overweight.

burden placed on health and social care resources, which will be critical to support those who survive COVID-19.

Author affiliations

- ¹Leicester Real World Evidence Unit, Leicester General Hospital, Leicester, UK
²Diabetes Research Centre, University of Leicester, Leicester, UK
³Big Data Institute, University of Oxford, Oxford, UK
⁴Department of Cardiovascular Sciences, University of Leicester, Leicester, UK
⁵Farr Institute of Health Informatics Research, University College London, London, UK
⁶Department of Cardiology, National Heart Centre Singapore, Singapore
⁷Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, UK
⁸Imperial College London, London, UK
⁹The Roslin Institute, The University of Edinburgh, Easter Bush Campus, UK
¹⁰University of Liverpool, Liverpool, UK

Twitter Amitava Banerjee @amibanerjee1 and Malcolm Gracie Semple @ProfCalumSemple

Acknowledgements This work uses data provided by patients and collected by the NHS as part of their care and support #DataSavesLives. The authors thank the 2648 front-line NHS clinical and research staff and volunteer medical students, who collected these data in challenging circumstances; and the generosity of the participants and their families for their individual contributions in these difficult times. The authors also thank Jeremy J Farrar and Nahoko Shindo for their support.

Collaborators ISARIC4C Investigators: United Kingdom: J Kenneth Baillie, Fiona Griffiths, Wilna Oosthuizen, Andrew Law, Sara Clohisey, Ross Hendry (Roslin Institute, University of Edinburgh). Malcolm G Semple, Tom Solomon, Lance CW Turtle, Hayley Hardwick (National Institute for Health Research [NIHR] Health Protection Research Unit, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool). Peter JM Openshaw, Ryan S Thwaites (National Heart and Lung Institute, Imperial College London). Gail Carson, Laura Merson, Louise Sigfrid (ISARIC Global Support Centre, Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford). Beatrice Alex, Benjamin Bach, James Scott-Brown (School of Informatics, University of Edinburgh). Wendy S Barclay (Section of Molecular Virology, Imperial College London). Debby Bogaert, Clark D Russell (Centre for Inflammation Research, The Queen's Medical Research Institute, University of Edinburgh). Meera Chand (Antimicrobial Resistance and Hospital Acquired Infection Department, Public Health England). Graham S Cooke, Shiranee Srisakandan (Department of Infectious Disease, Imperial College London). Annemarie B Docherty, Ewen M Harrison, Lisa Norman, Riinu Pius, Thomas M Drake, Cameron J Fairfield, Stephen R Knight, Kenneth A Mclean, Derek Murphy, Catherine A Shaw (Centre for Medical Informatics, The Usher Institute, University of Edinburgh). Jake Dunning, Maria Zambon (National Infection Service, Public Health England). Ana da Silva Filipe, Antonia Ying Wai Ho, Massimo Palmirani, David L Robertson, Janet T Scott, Emma C Thomson, Sarah E McDonald (Medical Research Council [MRC]-University of Glasgow Centre for Virus Research, University of Glasgow). Tom Fletcher (Liverpool School of Tropical Medicine). Christopher A Green (Institute of Microbiology and Infection, University of Birmingham). Julian A Hiscox (Institute of Infection and Global Health, University of Liverpool). Peter W Horby (Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford). Samreen Ijaz (Virology Reference Department, National Infection Service, Public Health England). Saye Khoo (Department of Pharmacology, University of Liverpool). Paul Klenerman (Nuffield Department of Medicine, Peter Medawar Building for Pathogen Research, University of Oxford). Andrew Law (The Roslin Institute, University of Edinburgh). Wei Shen Lim (Nottingham University Hospitals NHS Trust). Alexander J Mentzer (Nuffield Department of Medicine, John Radcliffe Hospital, Oxford). Alison M Meynert, Murray Wham (MRC Human Genetics Unit, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh). Mahdad Noursadeghi (Division of Infection and Immunity, University College London). Shona C Moore, William A Paxton, Georgios Pollakis (Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool). Nicholas Price (Centre for Clinical Infection and Diagnostics Research, Department of Infectious Diseases, School of Immunology and Microbial Sciences, King's College London). Andrew Rambaut (Institute of Evolutionary Biology, University of Edinburgh). Vanessa Sancho-Shimizu (Department of Pediatrics and Virology, Imperial College London). Thushan de Silva (The Florey Institute for Host-Pathogen Interactions, Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield). David Stuart (Division of Structural Biology, The Wellcome Centre for Human Genetics, University of Oxford). Charlotte Summers (Department of Medicine, University of Cambridge, Cambridge). Richard S Tedder (Blood Borne Virus Unit, Virus Reference Department, National Infection Service, Public Health England). AA Roger Thompson (Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield). Rishi K Gupta (Institute for Global Health, University College London). Carlo Palmieri (Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology, University of Liverpool). Olivia V Swann (Department of Child Life and Health, University of Edinburgh). Marc-Emmanuel Dumas, Julian L Griffin, Zoltan Takats, Petros Andrikopoulos, Anthonia Osagie, Michael Olanipekun, Sonia Liggi (Department of Metabolism, Digestion and Reproduction, Imperial College London). Kanta Chechi (Department of Epidemiology and Biostatistics, School of Public Health, Faculty of Medicine, Imperial College London). Matthew R Lewis, Gonçalo dos Santos Correia, Caroline J Sands, Panteleimon Takis, Lynn Maslen (National Phenome Centre, Department of Metabolism, Digestion and Reproduction, Imperial College London). Chloe Donohue, Jo Dalton, Michelle Girvan, Egle Saviciute, Stephanie Roberts, Janet Harrison, Laura Marsh, Marie Connor, Sophie Halpin, Clare Jackson, Carrol Gamble (Liverpool Clinical Trials Centre, University of Liverpool). Gary Leeming (Centre for Health Informatics, Division of Informatics, Imaging and Data Science, School of Health Sciences, University of Manchester). William Greenhalf (Department of Molecular and Clinical Cancer Medicine, University of Liverpool). Victoria Shaw (Institute of Translational Medicine, University of Liverpool, Liverpool, Merseyside, United Kingdom). Seán Keating (Intensive Care Unit, Royal Infirmary Edinburgh). Carlo Palmieri (University of Liverpool). Katie A Ahmed, Jane A Armstrong, Milton Ashworth, Innocent G Asimwe, Siddharth Bakshi, Samantha L Barlow, Laura Booth, Benjamin Brennan, Katie Bullock, Nicola Carlucci, Emily Cass, Benjamin WA Catterall, Jordan J Clark, Emily A Clarke, Sarah Cole, Louise Cooper, Helen Cox, Christopher Davis, Oslem Dincarslan, Alejandra Doce Carracedo, Chris Dunn, Philip Dyer, Angela Elliott, Anthony Evans, Lorna Finch, Lewis WS Fisher, Lisa Flaherty, Terry Foster, Isabel Garcia-Dorival, William Greenhalf, Philip Gunning, Catherine Hartley, Anthony Holmes, Rebecca L Jensen, Christopher B Jones, Trevor R Jones, Shadia Khandaker, Katharine King, Robyn T. Kiy, Chrysa Koukorava, Annette Lake, Suzannah Lant, Diane Latawiec, Lara Lavelle-Langham, Daniella Lefteri, Lauren Lett, Lucia A Livoti, Maria Mancini, Hannah Massey, Nicole Maziere, Sarah McDonald, Laurence McEvoy, John McLaughlan, Soeren Metelmann, Nahida S Miah, Joanna Middleton, Joyce Mitchell, Shona C Moore, Ellen G Murphy, Rebekah Penrice-Randal, Jack Pilgrim, Tessa Prince, Will Reynolds, P. Matthew Ridley, Debby Sales, Victoria E Shaw, Rebecca K Shears, Benjamin Small, Krishanthi S Subramaniam, Agnieszka Szemiel, Aislynn Taggart, Jolanta Tanianis-Hughes, Jordan Thomas, Erwan Trochu, Libby van Tonder, Eve Wilcock, J. Eunice Zhang (Outbreak Laboratory, University of Liverpool). Kayode Adeniji, Daniel Agranoff, Ken Agwuh, Dhiraj Ail, Erin L Aldera, Ana Alegria, Brian Angus, Abdul Ashish, Dougal Atkinson, Shahedal Bari, Gavin Barlow, Stella Barnass, Nicholas Barrett, Christopher Bassford, Sneha Basude, David Baxter, Michael Beadsworth, Jolanta Bernatoniene, John Berridge, Nicola Best, Pieter Bothma, Robin Brittain-Long, Naomi Bulteel, Tom Burden, Andrew Burtenshaw, Vikki Caruth, David Chadwick, David Chadwick, Duncan Chamblor, Nigel Chee, Jenny Child, Srikanth Chukkambotla, Tom Clark, Paul Collini, Catherine Cosgrove, Jason Cupitt, Maria-Teresa Cutino-Moguel, Paul Dark, Chris Dawson, Samir Dervisevic, Phil Donnison, Sam Douthwaite, Andrew Drummond, Ingrid DuRand, Ahilanadan Dushianthan, Tristan Dyer, Cariad Evans, Chi Eziefula, Christopher Fegan, Adam Finn, Duncan Fullerton, Sanjeev Garg, Sanjeev Garg, Atul Garg, Effrossyni Gkrania-Klotsas, Jo Godden, Arthur Goldsmith, Clive Graham, Elaine Hardy, Stuart Hartshorn, Daniel Harvey, Peter Havalda, Daniel B Hawcutt, Maria Hobrok, Luke Hodgson, Anil Hormis, Michael Jacobs, Susan Jain, Paul Jennings, Agilan Kaliappan, Vidya Kasipandian, Stephen Kegg, Michael Kelsey, Jason Kendall, Caroline Kerrison, Ian Kerslake, Oliver Koch, Gouri Koduri, George Koshy, Shondipon Laha, Steven Laird, Susan Larkin, Tamas Leiner, Patrick Lillie, James Limb, Vanessa Linnett, Jeff Little, Mark Lyttle, Michael MacMahon, Emily MacNaughton, Ravish Mankregod, Huw Masson, Elijah Matovu, Katherine McCullough, Ruth McEwen, Manjula Meda, Gary Mills, Jane Minton, Mariyam Mirfenderesky, Kavya Mohandas, Quen Mok, James Moon, Elinoor Moore, Patrick Morgan, Craig Morris, Katherine Mortimore, Samuel Moses, Mbiye Mpenge, Rohinton Mulla, Michael Murphy, Thapas Nagarajan, Megan Nagel, Mark Nelson, Lillian Norris, Matthew K. O'Shea, Marlies Ostermann, Igor Otahal, Mark Pais, Selva Panchatsharam, Danai Papakonstantinou, Padmasayee Papineni, Hassan Paraiso, Brij Patel, Natalie Pattison, Justin Pepperell, Mark Peters, Mandeep Phull, Stefania Pintus, Frank Post, David Price, Rachel Prout, Nikolas Rae, Henrik Reschreiter, Tim Reynolds, Neil Richardson, Mark Roberts, Devender Roberts, Alistair Rose, Guy Rousseau, Brendan Ryan, Taranprit Saluja, Sarah Cole, Aarti Shah, Manu Shankar-Hari, Prad Shanmuga, Anil Sharma, Anna Shawcross, Jagtur Singh Pooni, Jeremy Sizer, Richard Smith, Catherine Snelson, Nick Spittle, Nikki Staines, Tom Stambach, Richard Stewart, Pradeep Subudhi, Tamas Szakmany, Kate Tatham, Jo Thomas, Chris Thompson, Robert Thompson, Ascanio Tridente, Darell Tupper-Carey, Mary Twagira,

Nick Vallotton, Rama Vancheeswaran, Lisa Vincent-Smith, Shico Visuvanathan, Alan Vuylsteke, Sam Waddy, Rachel Wake, Andrew Walden, Ingeborg Welters, Tony Whitehouse, Paul Whittaker, Ashley Whittington, Meme Wijesinghe, Martin Williams, Lawrence Wilson, Stephen Winchester, Martin Wiselka, Adam Wolverson, Daniel G Wootton, Andrew Workman, Bryan Yates, Peter Young (local principal investigators).

Contributors TN and CAL analysed and interpreted the data and wrote the first draft. CAL and KK conceived of the study. CR contributed to data management. TY, FZ, NI, CLG, YVC, AR, MJD, GPM, AB, CSPL, ABD, PJMO, JKB and MGS read and provided critical feedback on the first draft of the manuscript and approved the final version. CAL and KK are the guarantors and accept full responsibility for the work and/or the conduct of the study, had access to the data, and controlled the decision to publish.

Funding This work was supported by the NIHR Leicester BRC, NIHR ARC-EM and a grant from the UKRI (MRC)-DHSC (NIHR) COVID-19 Rapid Response Rolling Call (MR/V020536/1), HDR-UK (HDRUK2020.138) the National Institute for Health Research (NIHR; award CO-CIN-01), the Medical Research Council (MRC; grant MC_PC_19059), and by the NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections at University of Liverpool. The funder/sponsor had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript; and decision to submit the manuscript for publication.

Competing interests KK is supported by the National Institute for Health Research (NIHR) Applied Research Collaboration East Midlands (ARC EM) and TY by the NIHR Leicester Biomedical Research Centre (BRC). KK is Director for the University of Leicester Centre for BME Health, Trustee of the South Asian Health Foundation, national NIHR ARC lead for Ethnicity and Diversity and a member of Independent SAGE and Chair of the SAGE subgroup on ethnicity and COVID-19. MGS is a member of HMG SAGE COVID-19. MGS reports grants from DHSC NIHR UK, grants from MRC UK, grants from HPRU in Emerging and Zoonotic Infections, University of Liverpool, during the conduct of the study, other from Integrum Scientific LLC, Greensboro, NC, USA, outside the submitted work. Other authors declare no conflicts of interests.

Patient consent for publication Not applicable.

Ethics approval The study was approved by the South Central - Oxford C Research Ethics Committee in England (Ref: 13/SC/0149), and by the Scotland Research Ethics Committee (Ref: 20/SS/0028).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data may be obtained from a third party and are not publicly available. Data and analysis scripts are available on request to the Independent Data Management and Access Committee at https://isaric4c.net/sample_access.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: <https://creativecommons.org/licenses/by/4.0/>.

ORCID iDs

Tom Norris <http://orcid.org/0000-0002-9140-0776>
 Gerry P McCann <http://orcid.org/0000-0002-5542-8448>
 Amitava Banerjee <http://orcid.org/0000-0001-8741-3411>
 Malcolm Gracie Semple <http://orcid.org/0000-0001-9700-0418>
 Claire Alexandra Lawson <http://orcid.org/0000-0003-0127-5236>

REFERENCES

- Bahl A, Van Baalen MN, Ortiz L, *et al*. Early predictors of in-hospital mortality in patients with COVID-19 in a large American cohort. *Intern Emerg Med* 2020;15:1485–99.
- Docherty AB, Harrison EM, Green CA, *et al*. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. *BMJ* 2020;369:m1985.
- Wiersinga WJ, Rhodes A, Cheng AC, *et al*. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. *JAMA* 2020;324:782–93.
- Petrilli CM, Jones SA, Yang J, *et al*. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. *BMJ* 2020;369:m1966.
- Maddaloni E, D'Onofrio L, Alessandri F, *et al*. Cardiometabolic multimorbidity is associated with a worse Covid-19 prognosis than individual cardiometabolic risk factors: a multicentre retrospective study (CoViDiab II). *Cardiovasc Diabetol* 2020;19:1–11.
- Richardson S, Hirsch JS, Narasimhan M, *et al*. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the new York City area. *JAMA* 2020;323:2052–9.
- Ferrari F. COVID-19: updated data and its relation to the cardiovascular system. *Arq Bras Cardiol* 2020;114:823–6.
- Xiong T-Y, Redwood S, Prendergast B, *et al*. Coronaviruses and the cardiovascular system: acute and long-term implications. *Eur Heart J* 2020;41:1798–800.
- Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA* 2020;323:1239–42.
- Guo T, Fan Y, Chen M, *et al*. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). *JAMA Cardiol* 2020;5:811–8.
- Petrovic V, Radenkovic D, Radenkovic G, *et al*. Pathophysiology of cardiovascular complications in COVID-19. *Front Physiol* 2020;11:575600.
- Yang D, Dalton JE. A unified approach to measuring the effect size between two groups using SAS. *SAS Global Forum* 2012;2012.
- OfN S. *Census: aggregate data*. 2016, 2011.
- Atkins JL, Masoli JAH, Delgado J, *et al*. Preexisting comorbidities predicting COVID-19 and mortality in the UK Biobank community cohort. *J Gerontol A Biol Sci Med Sci* 2020;75:2224–30.
- Yang J, Zheng Y, Gou X, *et al*. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. *Int J Infect Dis* 2020;94:91–5.
- Emami A, Javanmardi F, Pirbonyeh N, *et al*. Prevalence of underlying diseases in hospitalized patients with COVID-19: a systematic review and meta-analysis. *Arch Acad Emerg Med* 2020;8:e35.
- Doyle JF, Forni LG. Acute kidney injury: short-term and long-term effects. *Critical Care* 2016;20:1–7.
- Odutayo A, Wong CX, Farkouh M, *et al*. Aki and long-term risk for cardiovascular events and mortality. *J Am Soc Nephrol* 2017;28:377–87.
- Parikh CR, Coca SG, Wang Y, *et al*. Long-term prognosis of acute kidney injury after acute myocardial infarction. *Arch Intern Med* 2008;168:987–95.
- Wang H, Naghavi M, Allen C, *et al*. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the global burden of disease study 2015. *The Lancet* 2016;388:1459–544.
- Zádori N, Vánca S, Farkas N, *et al*. The negative impact of comorbidities on the disease course of COVID-19. *Intensive Care Med* 2020;46:1784–6.
- Jain V, Yuan J-M. Predictive symptoms and comorbidities for severe COVID-19 and intensive care unit admission: a systematic review and meta-analysis. *Int J Public Health* 2020;65:533–46.
- Zhou F, Yu T, Du R, *et al*. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020;395:1054–62.
- Ruan Q, Yang K, Wang W, *et al*. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Med* 2020;46:846–8.
- Buzon J, Roignot O, Lemoine S, *et al*. Takotsubo cardiomyopathy triggered by influenza A virus. *Intern Med* 2015;54:2017–9.
- Sze S, Pan D, Nevill CR, *et al*. Ethnicity and clinical outcomes in COVID-19: a systematic review and meta-analysis. *EclinicalMedicine* 2020;29-30:100630.
- Khunti K, Singh AK, Pareek M, *et al*. Is ethnicity linked to incidence or outcomes of covid-19? *BMJ* 2020;m1548.
- Tillin T, Forouhi NG, McKeigue PM, *et al*. Southall and Brent revisited: cohort profile of sabre, a UK population-based comparison of cardiovascular disease and diabetes in people of European, Indian Asian and African Caribbean origins. *Int J Epidemiol* 2012;41:33–42.
- Puntmann VO, Carerj ML, Wieters I, *et al*. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). *JAMA Cardiol* 2020;5:1265–73.

Supplementary material:

Impact of cardio-metabolic multimorbidity and ethnicity on cardiovascular and renal complications: an observational study in patients hospitalised with COVID-19

Tom Norris, PhD^{1,3} tdn9@leicester.ac.uk

Cameron Razieh, MSc^{1,2} cr288@leicester.ac.uk

Francesco Zaccardi, PhD^{1,3} fz43@leicester.ac.uk

Thomas Yates, PhD^{1,2} ty20@leicester.ac.uk

Nazrul Islam, PhD^{4,5} nazrul.Islam@ndph.ox.ac.uk

Clare L Gillies, PhD^{1,3} clg13@leicester.ac.uk

Yogini V Chudasama, PhD³ yc244@leicester.ac.uk

Alex Rowlands, PhD^{1,2} alex.rowlands@leicester.ac.uk

Melanie J Davies, MD^{1,2} melanie.davies@uhl-tr.nhs.uk

Gerry P McCann, MD^{2,4} gpm12@leicester.ac.uk

Ami Banerjee, MD PhD⁶ ami.banerjee@ucl.ac.uk

Carolyn Lam, MD PhD^{7,8} carolyn.lam@duke-nus.edu.sg

Annemarie B Docherty PhD^{9,10} annemarie.docherty@ed.ac.uk

Peter JM Openshaw, PhD¹¹ p.openshaw@imperial.ac.uk

J Kenneth Baillie, PhD¹² j.k.baillie@ed.ac.uk

Malcolm G Semple, PhD^{13,14} M.G.Semple@liverpool.ac.uk

ISARIC4C investigators*

Claire A. Lawson*, PhD^{3,4} cl417@leicester.ac.uk

Kamlesh Khunti, PhD^{1,3,15} kk22@leicester.ac.uk

*Joint senior author

Contents

Supplementary Text

Text S1. Testing	3
Text S2. Variable definitions	3
Table S1. Characteristics of those included in the final sample (n=65 624) vs those excluded for having incomplete exposure, covariate or outcome data (n= 49 457).....	5
Table S2. Univariate associations between presence of any baseline cardio-metabolic morbidities, number of baseline cardio-metabolic multi-morbidities, each individual cardio-metabolic morbidity, ethnicity and in-hospital cardiovascular and renal complications	6
Table S3. Association between any cardio-metabolic morbidity and any cardiovascular or renal complication: effect modification by ethnicity.....	7
Table S4. Association between cardio-metabolic multi-morbidity and any cardiovascular or renal complication: effect modification by ethnicity	8
Table S5. Association between individual cardio-metabolic morbidities, in-hospital cardiovascular and renal complications and death	9
Table S6. Association between baseline cardio-metabolic comorbidities and ‘cardiovascular and renal complications or all-cause death’	10
Table S7. Association between ethnicity and ‘cardiovascular and renal complications or all-cause death’	11
Table S8. Associations between baseline cardio-metabolic multi-morbidity, in-hospital cardiovascular and renal complications and death	12
Figure S1. Flow diagram outlining how final sample was derived.....	13
Figure S2. Association between any cardio-metabolic comorbidity and any cardiovascular or renal complication: modification by ethnicity	14
Figure S3. Association between cardio-metabolic multi-morbidity and any cardiovascular or renal complication: modification by ethnicity	15
Figure S4. Association between any cardio-metabolic comorbidity and ‘cardiovascular and renal complications or all-cause death’: modification by ethnicity.....	16
Figure S5. Association between cardio-metabolic multi-morbidity and ‘cardiovascular and renal complications or all-cause death’: modification by ethnicity.....	17

Text S1. Testing

The criteria to test for SARS-CoV-2 by PCR were not defined by the study; the decision to test was at the discretion of the clinician attending the patient. To support this, national guidance was provided by PHE and other UK public health agencies that advises who to test based on clinical case definitions for possible COVID-19, and also prioritisation of testing when demand exceeds capacity. In reality, anyone who was admitted to hospital and met the case definition for possible COVID-19 would have been tested, as capacity was never so limiting that hospital patients had to be triaged for testing.

We also included patients who had been admitted for a separate condition but had tested positive for covid-19 during their hospital stay.

Text S2. Variable definitions

Data were directly transcribed from routine healthcare into case report forms hosted on a REDCap database (Research Electronic Data Capture, <https://projectredcap.org>). Data collection was undertaken by research nurses, administrators and medical students. Detailed demographic and clinical data were collected on admission, with follow-up data on clinical care collected at day 3, 6, and 9 and discharge or status at 28 days if not discharged. The outcome of hospital admission was coded on discharge or death

Baseline cardio-metabolic comorbidities:

Chronic cardiac disease included any of the following: coronary artery disease, heart failure, congenital heart disease, cardiomyopathy and rheumatic heart disease. Obesity was defined by clinical staff, ideally but not necessarily, with an objective measurement of obesity, such as calculation of the body mass index (BMI of 30 or more) or measurement of abdominal girth. Chronic kidney disease was defined based on the presence of any of the following: clinician-diagnosed chronic kidney disease, chronic estimated glomerular filtration rate <60 mL/min/1.73m², history of kidney transplantation. Diabetes was defined as pre-existing clinician-diagnosed Type 1 or Type 2 diabetes. Similarly, hypertension was based on a pre-existing clinician diagnosis of hypertension.

Cardiovascular and renal complications:

Stroke was based on a clinical diagnosis, with or without supportive radiological findings. Heart failure was defined as failure of the heart to pump a sufficient amount of blood to meet the needs of the body tissues, resulting in tissue congestion and oedema. Cardiac arrhythmia was defined as presence of arrhythmia in those without a previous record of it, confirmed by electrocardiographic monitoring. Cardiac ischaemia was defined as diminished blood and oxygen supply to the heart muscle, also known as myocardial ischemia and was confirmed by an electrocardiogram (showing ischaemic changes, e.g. ST depression or elevation) and/or cardiac enzyme elevation. Cardiac arrest referred to the sudden cessation of cardiac activity with no normal breathing and no signs of circulation. Coagulation disorder was defined as abnormal coagulation identified by abnormal prothrombin time or activated partial thromboplastin time. Acute renal injury was defined as urine volume <0.5 mL/kg/hour for 6 hours or as a creatinine rise which corresponded to the Kidney Disease Improving Global Outcomes (KDIGO) stage I or above definition (increase in serum creatinine by ≥ 0.3 mg/dL (≥ 26.5 $\mu\text{mol/L}$) within 48 hours; increase in serum creatinine to ≥ 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days)¹.

1. Kellum JA, Lameire N, Aspelin P, Barsoum RS, Burdmann EA, Goldstein SL, Herzog CA, Joannidis M, Kribben A, Levey AS. Kidney disease: improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury. *Kidney international supplements* 2012;2(1):1-138.

Table S1. Characteristics of those included in the final sample (n=65 624) vs those excluded for having incomplete exposure, covariate or outcome data (n= 49 457)

	Included in final sample (n=65 624)		Excluded due to incomplete data (n=49 457)		Standardised differences [†]
	total n		total n		
Sex (male, n (%))	65 624	27 725 (56.1)	49 457	34 891 (53.2)	0.06
Age (years, mean (SD))	65 624	69.4 (18.0)	49 457	71.4 (16.3)	0.12
Ethnicity (n (%))					
White British		55 588 (84.7)		41 548 (84.0)	
South Asian	65 624	3 924 (6.0)	49 457	2 759 (5.6)	0.04
Black		1 709 (2.6)		1 488 (3.0)	
Other		4 403 (6.7)		3 662 (7.4)	
Any cardio-metabolic comorbidities on admission (yes, n (%))	65 624	44 598 (68.0)	30 651	29 797 (97.2)	0.84
In-hospital cardiovascular complications (yes, n(%))	65 624	16 628 (25.3)	38 183	10 854 (28.4)	0.07

[†] Standardized difference = difference in means or proportions divided by standard error; imbalance defined as absolute value greater than 0.10

Table S2. Univariate associations between presence of any baseline cardio-metabolic morbidities, number of baseline cardio-metabolic multi-morbidities, each individual cardio-metabolic morbidity, ethnicity and in-hospital cardiovascular and renal complications

	Primary outcome				Secondary outcome				
	Any complication	Death	Heart failure	Arrhythmia	Cardiac Ischaemia	Cardiac arrest	Coagulation complications	Stroke	Renal injury
	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)	OR (95% CI)
<i>Any cardio-metabolic comorbidity (ref: No)</i>	2.54 (2.43, 2.65)	2.12 (2.03, 2.22)	6.50 (5.53, 7.63)	2.05 (1.90, 2.22)	3.59 (2.91, 4.42)	1.56 (1.37, 1.77)	1.41 (1.27, 1.55)	1.61 (1.39, 1.86)	2.72 (2.57, 2.87)
<i>Number cardio-metabolic comorbidities (ref: 0)</i>									
1	1.79 (1.70, 1.88)	1.73 (1.65, 1.82)	3.10 (2.59, 3.72)	1.66 (1.52, 1.82)	2.38 (1.88, 3.01)	1.23 (1.06, 1.43)	1.30 (1.15, 1.46)	1.51 (1.28, 1.79)	1.85 (1.73, 1.97)
2	2.72 (2.59, 2.87)	2.30 (2.18, 2.42)	7.26 (6.12, 8.61)	2.13 (1.95, 2.33)	3.62 (2.87, 4.56)	1.77 (1.52, 2.05)	1.26 (1.11, 1.43)	1.65 (1.38, 1.96)	2.87 (2.69, 3.06)
>2	4.23 (4.00, 4.48)	2.77 (2.61, 2.93)	12.84 (10.83, 15.21)	2.78 (2.53, 3.05)	6.09 (4.84, 7.66)	1.91 (1.63, 2.25)	1.86 (1.63, 2.11)	1.75 (1.44, 2.12)	4.61 (4.31, 4.93)
<i>Ethnicity (ref: White)</i>									
South Asian	0.82 (0.75, 0.88)	0.66 (0.60, 0.71)	0.59 (0.47, 0.73)	0.67 (0.58, 0.77)	1.07 (0.81, 1.41)	1.45 (1.19, 1.76)	1.05 (0.87, 1.26)	0.79 (0.60, 1.05)	0.87 (0.79, 0.96)
Black	1.06 (0.95, 1.18)	0.64 (0.56, 0.72)	0.64 (0.47, 0.87)	0.69 (0.55, 0.86)	0.58 (0.33, 1.00)	1.72 (1.31, 2.25)	1.42 (1.12, 1.79)	0.71 (0.46, 1.11)	1.30 (1.15, 1.47)
Other	0.79 (0.73, 0.85)	0.63 (0.58, 0.68)	0.63 (0.51, 0.77)	0.71 (0.62, 0.81)	1.02 (0.78, 1.33)	0.96 (0.77, 1.20)	1.01 (0.85, 1.21)	0.87 (0.68, 1.13)	0.83 (0.76, 0.91)

Table S3. Association between any cardio-metabolic morbidity and any cardiovascular or renal complication: effect modification by ethnicity

	Any complication
	OR (95% CI)
Ethnicity (ref: White)	1.00
South Asian	1.03 (0.87 , 1.23)
Black	1.27 (0.99 , 1.61)
Other	1.07 (0.92, 1.24)
Any baseline cardio-metabolic comorbidity (ref: No)	
Yes	1.91 (1.82, 2.01)
Interaction	
White # No cardio-metabolic comorbidity (ref)	1.00
South Asian # Any cardio-metabolic comorbidity	1.11 (0.92 , 1.36)
Black # Any cardio-metabolic comorbidity	1.20 (0.91 , 1.58)
Other # Any cardio-metabolic comorbidity	0.97 (0.82 , 1.16)
<i>p (interaction)</i>	0.399

*adjusted for age and sex

Table S4. Association between cardio-metabolic multi-morbidity and any cardiovascular or renal complication: effect modification by ethnicity

	Any complication
	OR (95% CI)
Ethnicity (ref: White)	1.00
South Asian	1.00 (0.84, 1.19)
Black	1.23 (0.96, 1.56)
Other	1.04 (0.90, 1.21)
Baseline cardio-metabolic comorbidity	
0 (ref)	1.0
1	1.45 (1.37, 1.53)
2	2.02 (1.91, 2.14)
>2	3.07 (2.88, 3.27)
Interaction	
White#0.cardio-metabolic comorbidity (ref)	1.00
South Asian#1.cardio-metabolic comorbidity	1.12 (0.89, 1.41)
South Asian #2. cardio-metabolic comorbidity	1.01 (0.80, 1.29)
South Asian #3.cardio-metabolic comorbidity	1.18 (0.93, 1.50)
Black#1. cardio-metabolic comorbidity	1.17 (0.85, 1.61)
Black#2. cardio-metabolic comorbidity	1.24 (0.90, 1.71)
Black#3. cardio-metabolic comorbidity	1.24 (0.87, 1.77)
Other #1. cardio-metabolic comorbidity	0.98 (0.80, 1.20)
Other#2. cardio-metabolic comorbidity	1.04 (0.84, 1.29)
Other#3. cardio-metabolic comorbidity	0.95 (0.75, 1.19)
<i>p (interaction)</i>	0.807

*adjusted for age and sex

Table S5. Association between individual cardio-metabolic morbidities, in-hospital cardiovascular and renal complications and death

	Primary outcomes				Secondary outcomes				
	Any complication OR (95% CI)	Death OR (95% CI)	Heart failure OR (95% CI)	Arrhythmia OR (95% CI)	Cardiac Ischaemia OR (95% CI)	Cardiac arrest OR (95% CI)	Coagulation complications OR (95% CI)	Stroke OR (95% CI)	Renal injury OR (95% CI)
Individual baseline cardio-metabolic comorbidities*									
<i>Unadjusted</i>									
Diabetes	1.64 (1.57, 1.71)	1.34 (1.28, 1.40)	1.59 (1.44, 1.75)	1.25 (1.16, 1.35)	1.55 (1.33, 1.81)	1.45 (1.28, 1.64)	1.23 (1.11, 1.37)	1.21 (1.04, 1.40)	1.78 (1.70, 1.87)
Chronic cardiac disease	2.18 (2.10, 2.26)	2.08 (2.00, 2.16)	7.85 (7.12, 8.65)	2.04 (1.92, 2.17)	3.74 (3.25, 4.29)	1.45 (1.30, 1.62)	1.14 (1.04, 1.26)	1.46 (1.29, 1.65)	1.81 (1.73, 1.89)
Hypertension	1.81 (1.75, 1.88)	1.53 (1.48, 1.59)	2.21 (2.03, 2.42)	1.46 (1.37, 1.55)	1.89 (1.65, 2.17)	1.42 (1.27, 1.58)	1.14 (1.05, 1.25)	1.56 (1.38, 1.76)	1.91 (1.83, 1.99)
Chronic kidney disease	2.49 (2.38, 2.60)	2.08 (1.98, 2.17)	3.06 (2.80, 3.34)	1.49 (1.39, 1.61)	2.10 (1.80, 2.44)	1.26 (1.10, 1.45)	1.19 (1.06, 1.33)	1.15 (0.98, 1.35)	3.07 (2.92, 3.22)
Obesity	1.38 (1.32, 1.45)	0.82 (0.77, 0.86)	1.30 (1.16, 1.46)	1.43 (1.32, 1.55)	1.24 (1.03, 1.49)	1.27 (1.10, 1.47)	2.16 (1.95, 2.39)	0.81 (0.67, 0.99)	1.40 (1.32, 1.48)
<i>Adjusted**</i>									
Diabetes	1.48 (1.42, 1.55)	1.19 (1.13, 1.24)	1.50 (1.36, 1.65)	1.16 (1.08, 1.25)	1.38 (1.18, 1.61)	1.26 (1.11, 1.43)	1.15 (1.03, 1.27)	1.10 (0.95, 1.28)	1.61 (1.53, 1.69)
Chronic cardiac disease	1.69 (1.63, 1.76)	1.21 (1.16, 1.26)	5.77 (5.20, 6.39)	1.74 (1.63, 1.86)	3.03 (2.61, 3.51)	1.25 (1.11, 1.40)	1.27 (1.15, 1.41)	1.11 (0.97, 1.39)	1.39 (1.33, 1.46)
Hypertension	1.41 (1.35, 1.46)	0.97 (0.93, 1.01)	1.54 (1.41, 1.69)	1.22 (1.14, 1.30)	1.43 (1.24, 1.65)	1.16 (1.04, 1.30)	1.17 (1.06, 1.28)	1.22 (1.08, 1.39)	1.50 (1.43, 1.57)
Chronic kidney disease	2.02 (1.93, 2.11)	1.32 (1.26, 1.39)	2.12 (1.93, 2.32)	1.28 (1.19, 1.39)	1.66 (1.42, 1.94)	1.10 (0.95, 1.26)	1.35 (1.20, 1.52)	0.91 (0.77, 1.07)	2.58 (2.45, 2.71)
Obesity	1.83 (1.73, 1.92)	1.34 (1.26, 1.43)	2.13 (1.89, 2.40)	1.69 (1.55, 1.84)	1.62 (1.34, 1.96)	1.44 (1.24, 1.67)	2.03 (1.82, 2.25)	0.99 (0.81, 1.21)	1.81 (1.70, 1.93)

*separate models; ** adjusted for sex, age, and ethnicity

Table S6. Association between baseline cardio-metabolic comorbidities and ‘cardiovascular and renal complications or all-cause death’

	Cardiovascular and renal complications or all-cause death
	OR (95% CI)
<i>Any cardio-metabolic comorbidity (ref: No)*</i>	1.63 (1.57, 1.70)
<i>Number cardio-metabolic comorbidities (ref: 0)*</i>	
1	1.34 (1.28, 1.40)
2	1.69 (1.61, 1.77)
>2	2.38 (2.25, 2.51)
<i>Individual baseline cardio-metabolic comorbidities*</i>	
Diabetes	1.41 (1.36, 1.47)
Chronic cardiac disease	1.51 (1.46, 1.57)
Hypertension	1.21 (1.17, 1.26)
Chronic kidney disease	1.78 (1.70, 1.86)
Obesity	1.65 (1.57, 1.74)

*separate models, adjusted for sex, age, and ethnicity

Table S7. Association between ethnicity and ‘cardiovascular and renal complications or all-cause death’

		Cardiovascular and renal complications or all-cause death
		OR (95% CI)
<i>Ethnicity (ref: White)</i>		
	<i>South Asian</i>	1.19 (1.11, 1.29)
	<i>Black</i>	1.42 (1.27, 1.59)
	<i>Other</i>	1.04 (0.97, 1.12)

Table S8. Associations between baseline cardio-metabolic multi-morbidity, in-hospital cardiovascular and renal complications and death

	Death
	OR (95% CI)
Baseline cardio-metabolic conditions and in-hospital complications	
0 cardio-metabolic condition, 0 in-hospital complications (<i>ref</i>)	1.00
≥ 1 cardio-metabolic conditions, 0 in-hospital complications	1.20 (1.13, 1.27)
0 cardio-metabolic conditions, ≥ 1 in-hospital complications	3.92 (3.57, 4.29)
≥ 1 cardio-metabolic conditions, ≥ 1 in-hospital complications	3.17 (2.98, 3.37)
Adjusted for age, sex and ethnicity	

Figure S1. Flow diagram outlining how final sample was derived




Figure S2. Association between any cardio-metabolic comorbidity and any cardiovascular or renal complication: modification by ethnicity




Figure S3. Association between cardio-metabolic multi-morbidity and any cardiovascular or renal complication: modification by ethnicity




Figure S4. Association between any cardio-metabolic comorbidity and 'cardiovascular and renal complications or all-cause death': modification by ethnicity




Figure S5. Association between cardio-metabolic multi-morbidity and 'cardiovascular and renal complications or all-cause death': modification by ethnicity

